Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Phenotype-Driven Plasma Biobanking Strategies and Methods.

Bowton EA, Collier SP, Wang X, Sutcliffe CB, Van Driest SL, Couch LJ, Herrera M, Jerome RN, Slebos RJ, Alborn WE, Liebler DC, McNaughton CD, Mernaugh RL, Wells QS, Brown NJ, Roden DM, Pulley JM.

J Pers Med. 2015 May 14;5(2):140-52. doi: 10.3390/jpm5020140.

2.

Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma.

Lin D, Alborn WE, Slebos RJ, Liebler DC.

J Proteome Res. 2013 Dec 6;12(12):5996-6003. doi: 10.1021/pr400877e. Epub 2013 Nov 19.

3.

SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, Clark JE, Alborn WE, Eisenberg R, Massion PP.

Clin Cancer Res. 2013 Feb 1;19(3):560-70. doi: 10.1158/1078-0432.CCR-12-2334. Epub 2012 Dec 4.

4.

Development of a novel sandwich ELISA for measuring cell lysate ABCA1 protein levels.

Troutt JS, Alborn WE, Bellinger MA, Cox KL, Ehsani ME, Wang X, Qian YW, Sloan JH, Willey MB, Cao G, Konrad RJ.

Lipids. 2010 Aug;45(8):757-64. doi: 10.1007/s11745-010-3448-6. Epub 2010 Jul 17.

PMID:
20640528
5.

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

Troutt JS, Alborn WE, Cao G, Konrad RJ.

J Lipid Res. 2010 Feb;51(2):345-51. doi: 10.1194/jlr.M000620. Epub 2009 Sep 8.

6.

The development of methodology for clinical measurement of 5-lipoxygenase pathway intermediates from human peripheral blood mononuclear cells.

Willey MB, Alborn WE, Lutzke BS, Lelacheur RM, White RJ, Stavrakis G, Konrad RJ, Ackermann BL.

J Pharm Biomed Anal. 2008 Dec 15;48(5):1397-403. doi: 10.1016/j.jpba.2008.09.034. Epub 2008 Sep 30.

PMID:
18996667
7.

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):634-40. doi: 10.1016/j.bbrc.2008.04.004. Epub 2008 Apr 10.

PMID:
18406350
8.

An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma.

Troutt JS, Alborn WE, Mosior MK, Dai J, Murphy AT, Beyer TP, Zhang Y, Cao G, Konrad RJ.

J Lipid Res. 2008 Mar;49(3):581-7. Epub 2007 Dec 3.

9.

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ.

J Lipid Res. 2008 Feb;49(2):394-8. Epub 2007 Nov 21.

10.

Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA.

Sinha MK, Songer T, Xiao Q, Sloan JH, Wang J, Ji S, Alborn WE, Davis RA, Swarbrick MM, Stanhope KL, Wolfe BM, Havel PJ, Schraw T, Konrad RJ, Scherer PE, Mistry JS.

Clin Chem. 2007 Dec;53(12):2144-51. Epub 2007 Oct 19.

11.

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ.

Clin Chem. 2007 Oct;53(10):1814-9. Epub 2007 Aug 16.

12.

Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes.

Alborn WE, Prince MJ, Konrad RJ.

Clin Chim Acta. 2007 Mar;378(1-2):154-8. Epub 2006 Nov 24.

PMID:
17188674
13.

Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase.

Lee TN, Alborn WE, Knierman MD, Konrad RJ.

Biochem Biophys Res Commun. 2006 Dec 1;350(4):1038-43. Epub 2006 Oct 6.

PMID:
17045574
15.
16.

Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio.

Schultze AE, Alborn WE, Newton RK, Konrad RJ.

J Lipid Res. 2005 Aug;46(8):1591-5. Epub 2005 May 16.

17.

The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins.

O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ.

Clin Chem. 2005 Feb;51(2):351-9. Epub 2004 Nov 4.

18.

Genome of the bacterium Streptococcus pneumoniae strain R6.

Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR Jr, Skatrud PL, Glass JI.

J Bacteriol. 2001 Oct;183(19):5709-17.

19.

Identification and characterization of a monofunctional glycosyltransferase from Staphylococcus aureus.

Wang QM, Peery RB, Johnson RB, Alborn WE, Yeh WK, Skatrud PL.

J Bacteriol. 2001 Aug;183(16):4779-85.

21.
22.

Cloning and characterization of femA and femB from Staphylococcus epidermidis.

Alborn WE Jr, Hoskins J, Unal S, Flokowitsch JE, Hayes CA, Dotzlaf JE, Yeh WK, Skatrud PL.

Gene. 1996 Nov 21;180(1-2):177-81.

PMID:
8973364
23.

Antimicrobial characterization and interrelationships of dirithromycin and epidirithromycin.

Kirst HA, Creemer LC, Paschal JW, Preston DA, Alborn WE Jr, Counter FT, Amos JG, Clemens RL, Sullivan KA, Greene JM.

Antimicrob Agents Chemother. 1995 Jul;39(7):1436-41.

24.

Site-directed mutagenesis of the mecA gene from a methicillin-resistant strain of Staphylococcus aureus.

Wu CY, Alborn WE Jr, Flokowitsch JE, Hoskins J, Unal S, Blaszczak LC, Preston DA, Skatrud PL.

J Bacteriol. 1994 Jan;176(2):443-9.

25.

Inhibition of membrane potential-dependent amino acid transport by daptomycin.

Allen NE, Alborn WE Jr, Hobbs JN Jr.

Antimicrob Agents Chemother. 1991 Dec;35(12):2639-42.

26.

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Alborn WE Jr, Allen NE, Preston DA.

Antimicrob Agents Chemother. 1991 Nov;35(11):2282-7.

27.

Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones.

Jungheim LN, Boyd DB, Indelicato JM, Pasini CE, Preston DA, Alborn WE Jr.

J Med Chem. 1991 May;34(5):1732-9.

PMID:
2033596
28.

Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.

Gordee RS, Zeckner DJ, Howard LC, Alborn WE Jr, Debono M.

Ann N Y Acad Sci. 1988;544:294-309. No abstract available.

PMID:
3063174
29.

Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.

Allen NE, Hobbs JN, Alborn WE Jr.

Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9.

30.

Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.

Allen NE, Alborn WE Jr, Kirst HA, Toth JE.

J Med Chem. 1987 Feb;30(2):333-40.

PMID:
3543366
31.

Genetic and enzymatic basis of hygromycin B resistance in Escherichia coli.

Rao RN, Allen NE, Hobbs JN Jr, Alborn WE Jr, Kirst HA, Paschal JW.

Antimicrob Agents Chemother. 1983 Nov;24(5):689-95.

32.

7-Hydroxytropolone: an inhibitor of aminoglycoside-2"-O-adenylyltransferase.

Allen NE, Alborn WE Jr, Hobbs JN Jr, Kirst HA.

Antimicrob Agents Chemother. 1982 Nov;22(5):824-31.

Supplemental Content

Loading ...
Support Center